453 related articles for article (PubMed ID: 24373601)
41. Moving towards disease modification in inflammatory bowel disease therapy.
Allen PB; Peyrin-Biroulet L
Curr Opin Gastroenterol; 2013 Jul; 29(4):397-404. PubMed ID: 23695427
[TBL] [Abstract][Full Text] [Related]
42. Health-related quality of life in patients with inflammatory bowel disease: a Tunisian study.
Mnif L; Mzid A; Amouri A; Chtourou L; Tahri N
Tunis Med; 2010 Dec; 88(12):933-6. PubMed ID: 21136364
[TBL] [Abstract][Full Text] [Related]
43. Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy.
Ong DE; Kamm MA; Hartono JL; Lust M
J Gastroenterol Hepatol; 2013 Oct; 28(10):1595-9. PubMed ID: 23662928
[TBL] [Abstract][Full Text] [Related]
44. [Quality of life assessment in Inflammatory Bowel Disease (IBD): German version of the Inflammatory Bowel Disease Questionnaire (IBDQ-D; disease-specific instrument for quality of life assessment) -- first application and comparison with international investigations].
Janke KH; Steder-Neukamm U; Bauer M; Raible A; Meisner C; Hoffmann JC; Gregor M; Klump B; Häuser W
Gesundheitswesen; 2005; 67(8-9):656-64. PubMed ID: 16217720
[TBL] [Abstract][Full Text] [Related]
45. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
[TBL] [Abstract][Full Text] [Related]
46. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
[TBL] [Abstract][Full Text] [Related]
47. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
48. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
[TBL] [Abstract][Full Text] [Related]
49. Quality of Life--measurement in inflammatory bowel disease.
Irvine EJ
Scand J Gastroenterol Suppl; 1993; 199():36-9. PubMed ID: 8171299
[TBL] [Abstract][Full Text] [Related]
50. Predictive value of early restoration of quality of life in Crohn's disease patients receiving antitumor necrosis factor agents.
Herrera-deGuise C; Casellas F; Robles V; Navarro E; Borruel N
J Gastroenterol Hepatol; 2015 Feb; 30(2):286-91. PubMed ID: 25302652
[TBL] [Abstract][Full Text] [Related]
51. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
Boonen A; Patel V; Traina S; Chiou CF; Maetzel A; Tsuji W
J Rheumatol; 2008 Apr; 35(4):662-7. PubMed ID: 18278836
[TBL] [Abstract][Full Text] [Related]
52. Impact of complementary and alternative medicine on the quality of life in inflammatory bowel disease: results from a French national survey.
Abitbol V; Lahmek P; Buisson A; Olympie A; Poupardin C; Chaussade S; Lesgourgues B; Nahon S
Eur J Gastroenterol Hepatol; 2014 Mar; 26(3):288-94. PubMed ID: 24407360
[TBL] [Abstract][Full Text] [Related]
53. The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease.
Koutroubakis IE; Ramos-Rivers C; Regueiro M; Koutroumpakis E; Click B; Schwartz M; Swoger J; Baidoo L; Hashash JG; Barrie A; Dunn MA; Binion DG
Inflamm Bowel Dis; 2015 Jul; 21(7):1587-93. PubMed ID: 25933393
[TBL] [Abstract][Full Text] [Related]
54. The burden of inflammatory bowel disease on health care utilization and quality of life.
Nurmi E; Haapamäki J; Paavilainen E; Rantanen A; Hillilä M; Arkkila P
Scand J Gastroenterol; 2013 Jan; 48(1):51-7. PubMed ID: 22577851
[TBL] [Abstract][Full Text] [Related]
55. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
56. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
Deepak P; Stobaugh DJ; Ehrenpreis ED
J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
[TBL] [Abstract][Full Text] [Related]
57. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients.
Mohabbat AB; Sandborn WJ; Loftus EV; Wiesner RH; Bruining DH
Aliment Pharmacol Ther; 2012 Sep; 36(6):569-74. PubMed ID: 22779779
[TBL] [Abstract][Full Text] [Related]
58. [Immune response to biological therapy of inflammatory bowel diseases].
Kniazev OV; Parfenov AI; Ruchkina IN; Lazebnik LB; Sagynbaeva VÉ
Ter Arkh; 2013; 85(12):55-9. PubMed ID: 24640669
[TBL] [Abstract][Full Text] [Related]
59. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.
Olivieri I; Cortesi PA; de Portu S; Salvarani C; Cauli A; Lubrano E; Spadaro A; Cantini F; Ciampichini R; Cutro MS; Mathieu A; Matucci-Cerinic M; Punzi L; Scarpa R; Mantovani LG;
Clin Exp Rheumatol; 2016; 34(1):68-75. PubMed ID: 26633622
[TBL] [Abstract][Full Text] [Related]
60. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis.
Bernklev T; Jahnsen J; Schulz T; Sauar J; Lygren I; Henriksen M; Stray N; Kjellevold Ø; Aadland E; Vatn M; Moum B
Eur J Gastroenterol Hepatol; 2005 Oct; 17(10):1037-45. PubMed ID: 16148548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
